Tailored lipid nanoparticle formulation and evaluation solutions for efficient miRNA delivery.
MicroRNAs (miRNAs) are short non-coding RNA molecules with powerful gene-regulatory potential, but their therapeutic exploration is limited by enzymatic degradation, poor membrane permeability, rapid clearance, off-target distribution, and inefficient cytosolic release. Lipid nanoparticles (LNPs) provide a flexible non-viral delivery platform for protecting miRNA mimics, inhibitors, and chemically modified miRNA oligonucleotides while enabling tunable particle size, surface properties, encapsulation performance, and cellular uptake behavior. BOC Sciences offers specialized services for lipid nanoparticles for RNA delivery, supporting researchers in designing, optimizing, and evaluating LNP systems for miRNA-based drug discovery, functional genomics, disease model studies, and targeted nanomedicine research. Our service integrates lipid composition screening, microfluidic formulation, encapsulation optimization, physicochemical characterization, stability assessment, and biological performance evaluation to help clients identify robust LNP candidates matched to their miRNA cargo and application objectives.
Lipid nanoparticle encapsulating miRNA cargoWe provide an integrated development framework for miRNA-loaded LNPs, from early formulation design to performance-oriented optimization. Each project is customized according to miRNA sequence length, chemical modification, target cell type, administration route for research use, and desired intracellular activity profile.
We design LNP formulations based on the physicochemical properties of miRNA cargo and the intended biological model. Our formulation strategy balances encapsulation, colloidal stability, cellular uptake, and RNA release behavior.
Efficient encapsulation is essential for protecting miRNA from nuclease degradation and maintaining formulation consistency. We optimize loading conditions to achieve stable association between miRNA and the LNP core.
The delivery performance of miRNA-LNPs is highly dependent on lipid composition. We help clients compare lipid libraries and identify formulations that support endosomal escape and cellular activity.
We support LNP development for different miRNA cargo formats, including miRNA mimics, antagomirs, miRNA inhibitors, and chemically modified oligonucleotide analogs.
For projects requiring improved tissue or cell-type preference, we develop surface-modified LNPs that incorporate targeting ligands or functional motifs without compromising miRNA encapsulation.
We provide comprehensive analytical characterization to understand how formulation variables affect miRNA protection, particle behavior, and delivery performance.
miRNA delivery requires more than simple RNA encapsulation. A successful LNP system must protect the oligonucleotide, interact with target cells, escape endosomes, and release the miRNA in a form capable of engaging intracellular RNA-induced silencing pathways. BOC Sciences develops formulation strategies around these linked requirements.
From lipid screening to cellular performance evaluation, BOC Sciences helps researchers identify miRNA delivery systems with improved protection, uptake, and functional activity.
Our LNP development services are adaptable to diverse miRNA structures, formulation goals, and biological research models. We select analytical and formulation strategies based on cargo chemistry, target cells, desired activity readout, and nanoparticle performance requirements.
| Service Category | Technical Scope and Application Focus |
|---|---|
| Lipid Nanoparticles for miRNA Mimics | Formulation of double-stranded miRNA mimics for cellular gain-of-function studies, target pathway investigation, and RNA-based discovery projects. |
| miRNA Inhibitor LNPs | Development of LNP systems for antisense miRNA inhibitors, antagomirs, and chemically modified oligonucleotides designed to suppress endogenous miRNA activity. |
| Fluorescent miRNA-LNPs | Preparation of labeled miRNA or lipid-labeled LNPs for uptake tracking, intracellular localization studies, and formulation comparison. |
| Targeted miRNA-LNPs | Surface-modified LNPs incorporating ligands such as peptides, carbohydrates, or antibody fragments for receptor-associated uptake evaluation. |
| Serum-Stable miRNA-LNPs | Formulation optimization to reduce aggregation, miRNA leakage, and nuclease-sensitive degradation under serum-containing conditions. |
| Cell-Type-Oriented LNP Screening | Comparative screening in hepatocyte-like cells, immune cells, tumor-derived cell lines, epithelial cells, or other customer-selected cell models. |
| Endosomal Escape-Oriented LNPs | Lipid composition and helper lipid tuning to improve cytosolic delivery rather than only increasing total cellular association. |
| Process-Optimized miRNA-LNPs | Parameter mapping for mixing condition, buffer exchange, concentration, and storage handling to support reproducible formulation preparation. |
miRNA-loaded LNPs often fail because particle formation, RNA protection, uptake, and intracellular release are not optimized together. BOC Sciences helps clients troubleshoot these interconnected barriers.
✔ Low miRNA Encapsulation
Short RNA length, sequence-dependent structure, and suboptimal N/P ratio can produce high free miRNA levels. We optimize lipid composition, buffer conditions, and mixing parameters to improve encapsulation and reduce cargo loss.
✔ Poor Serum Stability
miRNA-LNPs may aggregate, leak RNA, or lose activity after dilution in protein-rich media. We evaluate formulation robustness under serum-containing conditions and adjust PEG-lipid, cholesterol, and helper lipid levels.
✔ Weak Cellular Uptake
A formulation with good encapsulation may still show limited cell entry. We assess size, surface charge, PEG shielding, and ligand presentation to improve cellular association in selected research models.
✔ Inefficient Endosomal Escape
Strong uptake does not guarantee functional miRNA activity. We optimize ionizable lipid and helper lipid combinations to improve endosomal membrane interaction and cytosolic release.
✔ Off-Target Cell Interaction
Non-specific uptake can complicate biological interpretation. We design targeted or shielded LNP formats and compare uptake profiles across relevant and non-relevant cell models.
✔ Unclear Structure-Activity Relationship
Clients often receive particle size data without understanding why activity changes. We connect formulation parameters, physicochemical attributes, and biological readouts to identify the variables that drive miRNA performance.
We review the miRNA format, sequence length, chemical modifications, concentration range, target cell model, and desired functional readout to define a rational formulation plan.
Multiple LNP compositions and mixing conditions are screened using lipid nanoparticle formulation strategies, with focus on encapsulation efficiency, size distribution, and colloidal behavior.
Candidate formulations are evaluated for particle size, PDI, zeta potential, morphology, encapsulated miRNA fraction, RNA integrity, and stability under project-relevant media conditions.
Selected formulations are examined through in vitro uptake, intracellular localization, endosomal escape, and functional miRNA activity assays to identify candidates with the strongest overall delivery profile.
Challenge: A research group developing a miRNA mimic for tumor suppressor pathway studies observed high total cellular fluorescence after LNP treatment, but qPCR analysis showed only weak downregulation of the intended target transcript. Initial particle size was approximately 145 nm with a PDI above 0.25, suggesting heterogeneous assembly.
Diagnosis: BOC Sciences compared four lipid compositions and found that the original formulation supported miRNA association but provided insufficient endosomal release. Fluorescence microscopy indicated strong punctate intracellular signals, consistent with endosomal retention rather than productive cytosolic delivery.
Solution: We redesigned the formulation using a higher proportion of pH-responsive ionizable lipid and screened two helper lipid systems with different membrane-disruptive properties. Microfluidic mixing conditions were adjusted by changing the aqueous-to-organic flow rate ratio and reducing the total lipid concentration to narrow the particle size distribution. The optimized formulation reached a particle size near 90 nm with a PDI below 0.18 and maintained strong miRNA encapsulation after buffer exchange.
Result: Among six screened candidates, one formulation produced the clearest functional profile, with stronger target mRNA knockdown at the same miRNA input and reduced punctate endosomal retention compared with the starting formulation. The client used the optimized candidate for follow-up pathway analysis in 2D and spheroid tumor cell models.
Challenge: A biotechnology team working with a chemically modified miRNA inhibitor required an LNP system that could remain dispersed after dilution into serum-containing medium. Their original formulation showed rapid particle growth from below 120 nm to above 250 nm within several hours and produced inconsistent cellular activity.
Diagnosis: We analyzed particle size, PDI, zeta potential, and free miRNA inhibitor fraction before and after serum exposure. The data suggested that the formulation had insufficient steric stabilization and partial cargo leakage after dilution, while excessive PEG-lipid in a separate trial reduced cellular uptake.
Solution: BOC Sciences prepared a focused formulation matrix varying PEG-lipid molar percentage, cholesterol ratio, and N/P ratio. We also compared two post-formulation buffer exchange conditions to reduce osmotic stress. Candidate LNPs were evaluated after 0, 4, and 24 hours in serum-containing medium, followed by in vitro uptake and target miRNA inhibition readouts.
Result: The best-performing formulation maintained particle size variation within an acceptable research-defined window over 24 hours, reduced free miRNA inhibitor signal, and preserved cellular activity without the uptake loss observed at higher PEG-lipid content. This gave the client a more reliable formulation basis for mechanistic studies.
miRNA-Specific Formulation LogicWe do not simply transfer mRNA or siRNA protocols to miRNA projects. Our team considers miRNA length, strand format, chemical modification, and activity mechanism when designing LNP systems.
Integrated Formulation and TestingWe connect LNP preparation, encapsulation analysis, stability testing, and cell-based performance evaluation so that formulation decisions are guided by practical delivery outcomes.
Advanced Process OptimizationThrough LNP process optimization, we refine mixing parameters, buffer conditions, and composition variables to improve reproducibility and particle quality.
Functional Delivery ReadoutsWe evaluate not only whether miRNA enters cells, but whether it produces measurable intracellular activity through reporter systems, target gene modulation, or pathway-associated readouts.
Flexible Targeting OptionsOur LNP platform can be adapted for non-targeted, ligand-modified, or cell-type-oriented delivery designs to support diverse miRNA research objectives.
Lipid nanoparticles (LNPs) are highly suitable for miRNA delivery because they address several core limitations of naked miRNA molecules, including nuclease degradation, negative charge, poor membrane permeability, and inefficient intracellular delivery. miRNA typically needs to reach the cytoplasm to regulate target gene expression, while unprotected miRNA is rapidly degraded and cannot efficiently cross cell membranes. LNPs can encapsulate or complex miRNA through ionizable lipid interactions, protect it during extracellular exposure, and promote endosomal escape after cellular uptake. For drug development researchers, the value of LNPs lies not only in miRNA loading but also in the tunability of lipid composition, N/P ratio, particle size, surface charge, and stability. BOC Sciences can support miRNA-LNP formulation screening, encapsulation efficiency analysis, particle characterization, and release behavior evaluation for early-stage delivery optimization.
The most common challenges in miRNA-LNP development include insufficient miRNA encapsulation, unstable particle size distribution, aggregation after dilution or storage, premature miRNA leakage in serum-containing environments, and limited endosomal escape after cellular uptake. Many projects initially focus on whether the particle size is acceptable, but overlook whether the miRNA is truly encapsulated, remains intact, and is separated from the free fraction. In addition, ionizable lipids, PEG-lipids, and light scattering from intact nanoparticles may interfere with conventional nucleic acid quantification. Different miRNA sequences, lengths, and chemical modifications may require different formulation parameters. Therefore, a rational screening matrix covering lipid ratio, N/P ratio, buffer pH, mixing conditions, and analytical readouts is often needed to identify the most promising formulation design.
miRNA encapsulation in LNPs should be evaluated by distinguishing free miRNA, surface-associated miRNA, and miRNA protected inside the nanoparticle structure. A commonly used approach is a fluorescent dye accessibility assay, in which samples are measured under two conditions: intact LNPs without disruption and fully lysed LNPs after surfactant treatment. The signal difference can be used to calculate encapsulation efficiency. When needed, ultrafiltration, size exclusion chromatography, or centrifugation-based separation can be used to remove unencapsulated miRNA before analysis. Additional methods such as gel electrophoresis, fluorescence-based quantification, or RNA integrity analysis may be applied to confirm that the miRNA remains intact. A robust assessment should also include particle size, PDI, zeta potential, total miRNA loading, and leakage behavior under relevant buffer or serum conditions.
Optimizing miRNA-LNP delivery performance usually requires coordinated adjustment of both formulation composition and preparation process. In the formulation, ionizable lipids influence miRNA complexation and endosomal escape, helper lipids and cholesterol affect membrane stability, and PEG-lipids contribute to particle size control and colloidal behavior. In the preparation process, aqueous-to-organic phase ratio, total flow rate, mixing speed, miRNA concentration, N/P ratio, and buffer pH can all influence nanoparticle formation. A practical optimization strategy is to establish a small-scale screening matrix and compare formulations using particle size, PDI, encapsulation efficiency, cellular uptake, miRNA functional readout, and stability data. For targeted delivery projects, ligand modification or tissue-preferential lipid design may also be considered, but formulation selection should be guided by reproducible physicochemical and functional data rather than a single parameter.
BOC Sciences can support multiple key aspects of miRNA-LNP research, including formulation development, microfluidic preparation optimization, particle size and PDI analysis, zeta potential measurement, encapsulation efficiency and loading analysis, free miRNA removal strategy evaluation, release and leakage studies in buffer or serum-containing systems, and cell-based uptake or functional assessment. For early exploratory projects, we can help compare the effects of ionizable lipid ratio, N/P ratio, PEG-lipid content, and preparation conditions on particle quality and miRNA loading. For projects with existing candidate formulations, we can further develop analytical workflows tailored to the specific miRNA sequence and lipid system. Our goal is to provide interpretable and comparable data that help drug development teams select better LNP designs for delivery performance optimization and mechanistic research.
